Received Mar 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Dizzy; Nausea; room spinning/room going round; This non-serious case was reported by a consumer via call center representative and described the occurrence of dizziness in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 14-NOV-2025, the patient received Shingrix. On 14-NOV-2025, 1 min after receiving Shingrix, the patient experienced dizziness (Verbatim: Dizzy), nausea (Verbatim: Nausea) and spinning sensation (Verbatim: room spinning/room going round). On 14-NOV-2025, the outcome of the dizziness, nausea and spinning sensation were resolved (duration 5 hrs). It was unknown if the reporter considered the dizziness, nausea and spinning sensation to be related to Shingrix. It was unknown if the company considered the dizziness, nausea and spinning sensation to be related to Shingrix. Additional Information: GSK receipt date: 10-MAR-2026 The patient received the Shingrix vaccine on 14-NOV-2025 (approximately), and within one minute he began to feel dizzy, experienced a sensation of the room spinning, and felt nauseated. These symptoms lasted for about four to five hours. He then recovered from those symptoms and had not experienced them since. The batch number was not provided upon follow up with the reporter.